This website uses cookies

This websites contains videos from YouTube. This company uses cookies (third party cookies). If you do not want them to use these cookies, you can indicate so here. However, this does mean that you will not be able to watch videos on this website. We also make use of our own cookies in order to improve our website. We don't share our data with other parties. Which cookies are involved?

This website uses cookies to enable video and to improve the user experience. If you do not want to accept these cookies, indicate so here. Which cookies are involved?

Ga direct naar de inhoud, het hoofdmenu, het servicemenu of het zoekveld.

Senior Bioinformaticus with experience in tumor immunology

Your function within the department

A Senior Bioinformatician position is available in the laboratory of Dr Christian Blank, Dept. Molecular Oncology and Immunology, at the Netherlands Cancer Institute, Amsterdam.

Our group has pioneered neoadjuvant immunotherapy in melanoma, and focuses on understanding pre-requisites for response upon neoadjuvant immunotherapy, better patient selection, and subsequent personalized combination therapies of targeted and immunotherapies.

Our group consists of basic researchers and physician researchers to ensure the direct translation of our laboratory findings into early phase clinical trials, and also back to bench. Your project will focus on gaining understanding on modulation of tumor immune infiltration, big data analysis of patient cohorts treated with neoadjuvant checkpoint inhibition, and high throughput screens identifying new modulators of immune activation.

Your profile

We offer a position for an ambitious and highly motivated candidate with a passion for computational biology, translational research and cancer immunotherapy. A solid track record and a background in bioinformatics, computer science or a related discipline with extensive experience with high-throughput data analysis, especially sequencing data is expected. Proficiency in bioinformatics programming languages (e.g. R, Python). Good cross-disciplinary collaborative and communication skills. Experience  in  statistics,  machine  learning  and experience with projects involving genomics to identifying candidate targets and biomarkers is  a plus. Knowledge of tumor immunology and animal models will be an advantage.

Your career opportunities and terms of employment

You will join a dynamic international research group, that is embedded in the division of molecular oncology and immunology, consisting of a large team of scientists that are headed by seven PIs (Thommen, Kvistborg, Haanen, Peeper, Schumacher, Voest, and Blank).
You will collaborate with scientists and clinicians with expertise in different disciplines, all focusing on cancer immunotherapies. You will have the opportunity to follow high-quality courses offered by the NKI postdoc career development program.

Your temporary employment will be initially for a period of two years. The gross salary per month will range from € 2.798,- to € 4.111,- according to the FWG-function group 55, and depends on previous experience. The terms of employment will be in accordance with the CAO Ziekenhuizen (Collective Labour Agreement for Hospitals


For further information about the position, please contact Prof. Dr. Christian Blank.

Applications can be submitted through the link below, and should include your CV, a motivation letter, and the contact information of your references.

Selected reading

Rozeman EA, Menzies AM van Akkooi ACJ, Adhikari C, Bierman C, van de Wiel BA, Scolyer RA, Krijgsman O, Sikorska K, Eriksson H, Broeks A, van Thienen JV, Guminski AD, Torres Acosta A, ter Meulen S, Koenen AM, Bosch LJ, Shannon K, Pronk LM, Gonzalez M, Ch’ng S, Emanuelsson H, Grijpink-Ongering LG, Stretch J, Heijmink S, van Tinteren H, Haanen JBAG, Nieweg OE, Klop WMC, Zuur CL, Saw RPM, van Houdt WJ, Peeper DS, Spillane AJ, Hansson J, Schumacher TN, Long GV, and Blank CU. Identification of a favourable combination scheme of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma: a multicentre randomised phase 2 study (OpACIN-neo). Lancet Oncol. 2019 Jul;20(7):948-960

O'Donnell JS, Hoefsmit EP, Smyth MJ, Blank CU, Teng MWL. The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment. Clin Cancer Res. 2019 Apr 30